Table 4.

Summary the results of gastrectomy following systemic chemotherapy for stage IV gastric cancer

Reference	Author	Year	Metastasis	Regimen of chemotherapy	Patients who underwent gastrectomy		Whole study population (if it included non-surgery cases)		Prognostic factors
					Number of patients	MST (months)	Number of patients	MST (months)
12	Nakajima et al.	1997	M1	FLEP (5-Fluorouracil, Leucovorin, Cisplatin, Etoposide)	19	NA	30	6.5	NA
13	Yano et al.	2002	unresectable (M0 + M1)	FEMTXP (5-Fluorouracil, Epirubicin, Methotrexate, Cisplatin) or THP-FLPM (Pirarubicin,5-Fluorouracil, Leucovorin, Cisplatin, Mitomycin C)	14	NA	33	NA	salvage surgery
14	Satoh et al.	2006	M0 + M1	S-1, Cisplatin	36	NA	45	21.8	NA
15	Ishigami et al.	2008	M1	Paclitaxel, S-1	18	25.7	–	–	R0 resection
16	Okabe et al.	2009	M1 (peritoneal metastasis)	S-1, Cisplatin	32	NA	41	20.4	NA
17	Suzuki et al.	2010	unresectable (M0 + M1)	Docetaxel, S-1	20	28.5	–	–	NA
18	Kanda et al.	2012	M1	S-1 based chemotherapy	28	29.0	–	–	histological tumor length (<  5 cm vs. ≥ 5 cm)
19	Satoh et al.	2012	M1	S-1, Cisplatin	44	NA	51	19.2	NA
20	Han et al.	2013	M1	Various	34	22.9 (R0 resection) and 7.8 (non-R0 resection)	–	–	ypN stage (N0–2 vs. N3)
21	Yabusaki et al.	2013	M1	S-1, Cisplatin	97	22.5	148	16.8	surgery, R0 resection, D2/D3 lymph node dissection, CR/PR response
22	Fukuchi et al.	2015	unresectable (M0 + M1)	S-1, Cisplatin or S-1, Paclitaxel	40	53.0	151	16.0	one non-curative factor, R0 resection
23	Kinoshita et al.	2015	M1	Docetaxel, Cisplatin, S-1	34	29.9	57	20.9	potential resectability
24	Ito et al.	2015	M1	Various	14	24.8	70	14.1	NA
Present study			M1	Various	101	26.0	–	–	curative resection (complete macroscopic resection), chemotherapy response (CR/PR) of metastatic site, change of CEA level

MST median survival time, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available, CEA carcinoembryonic antigen